Edition:
India

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

75.56USD
1:54am IST
Change (% chg)

$3.65 (+5.08%)
Prev Close
$71.91
Open
$73.29
Day's High
$75.79
Day's Low
$71.83
Volume
205,910
Avg. Vol
201,682
52-wk High
$76.17
52-wk Low
$10.74

Select another date:

Fri, Dec 15 2017

BRIEF-Esperion Announces The Appointment Of Jeffrey Berkowitz To Board Of Directors

* ESPERION ANNOUNCES THE APPOINTMENT OF JEFFREY BERKOWITZ TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Esperion Therapeutics Q3 loss per share $1.86‍​

* Esperion provides bempedoic acid franchise development program updates; reports third quarter 2017 financial results

BRIEF-Esperion announces initiation of pivotal late stage study for bempedoic acid

* Esperion announces initiation of pivotal late stage study for the bempedoic acid / ezetimibe combination pill

BRIEF-Esperion Therapeutics - Phase 3 results for bempedoic acid expected in Q2, Q3 2018

* Esperion Therapeutics- bempedoic acid top-line results from studies 1, 3 and 4 are expected in Q2 2018, results from study 2 expected in Q3 2018

BRIEF-Meditor Group Ltd reports 8.2 pct passive stake in Esperion Therapeutics Inc

* Meditor Group Ltd reports 8.2 percent passive stake in Esperion Therapeutics Inc as on Aug 10 - SEC filing​ Source text (http://bit.ly/2x6jGbc) Further company coverage:

BRIEF-Esperion announces proposed public offering of common stock

* Esperion announces proposed public offering of common stock

BRIEF-Co announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin​

* Says Esperion announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin​

BRIEF-Esperion reports initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor

* Esperion announces initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor

Select another date: